SCOLR PHARMA ENTERS RESEARCH COLLABORATION TO CO-DEVELOP NOVEL FLU APPLICATION

SCOLR Pharma, Inc. announced that it has entered into a research collaboration with a US-based biopharmaceutical company to develop an oral formulation of a promising antiviral compound using SCOLR's proprietary CDT drug delivery platform. The compound under development has the potential to be used as a treatment against influenza. The goal of the program is to enhance the bioavailability of our partner's compound to facilitate oral administration. If successful, the parties expect to enter a license agreement which would provide for the potential commercialization of a significant new pharmaceutical product.

BioSpace (http://www.biospace.com/news.aspx#breakingnews)